title: A review of onabotulinumtoxinA (Botox).
abstract: OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.
authors.affiliation: Private practice in New York, New York, USA. lorenc@lorenc.com
authors.forename: Z Paul
authors.initials: ZP
authors.lastname: Lorenc
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Kenkel
authors.forename: Steven
authors.initials: S
authors.lastname: Fagien
authors.forename: Haideh
authors.initials: H
authors.lastname: Hirmand
authors.forename: Mark S
authors.initials: MS
authors.lastname: Nestor
authors.forename: Anthony P
authors.initials: AP
authors.lastname: Sclafani
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Sykes
authors.forename: Heidi A
authors.initials: HA
authors.lastname: Waldorf
mesh_terms: D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D006801:Humans; D012060:Rejuvenation
chemical_list: D019274:Botulinum Toxins, Type A